ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Real-World Effectiveness and Safety of Imeglimin in Type 2 Diabetes: Prospective Multi-Center Study in Bangladesh.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assessed the real-world effectiveness and safety of imeglimin among Bangladeshi patients with type 2 diabetes mellitus (T2DM). Methods: This prospective, multi-center observational study was conducted across 15 specialized diabetes care centers in Bangladesh from January 2024 to December 2024. Adults with uncontrolled T2DM (HbA1c >7%) prescribed imeglimin (500-2000 mg daily) either as monotherapy or combination therapy were enrolled. A total of 898 subjects were assessed at baseline, 3 months, and 6 months. Primary outcomes were changes in HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPPG). Secondary outcomes included body mass index (BMI), blood pressure, lipids, and safety parameters. Results: The mean age was 46.2 ± 13.1 (SD) years, with 67% being female. Baseline HbA1c decreased from 9.2±1.4% to 7.1±1.0% at 6 months (mean change: -2.1%, p<0.001). FPG reduced from 9.37±2.53 to 7.28±4.63 mmol/L (p<0.001) and PPPG from 14.36±3.29 to 8.95±1.76 mmol/L (p<0.001). BMI decreased from 28.1±4.2 to 25.6±3.6 kg/m Conclusion: Imeglimin demonstrated substantial glycemic improvements and favorable safety in real-world Bangladeshi patients with poor glycemic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.